RT Journal Article
SR Electronic
T1 A multi-site, multi-participant magnetoencephalography resting-state dataset to study dementia: The BioFIND dataset
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257330
DO 10.1101/2021.05.19.21257330
A1 Vaghari, Delshad
A1 Bruna, Ricardo
A1 Hughes, Laura E.
A1 Nesbitt, David
A1 Tibon, Roni
A1 Rowe, James B.
A1 Maestu, Fernando
A1 Henson, Richard N.
YR 2021
UL http://medrxiv.org/content/early/2021/05/19/2021.05.19.21257330.abstract
AB Early detection of Alzheimer’s Disease (AD) is vital to reduce the burden of dementia and for developing effective treatments. Neuroimaging can detect early brain changes, such as hippocampal atrophy in Mild Cognitive Impairment (MCI), a prodromal state of AD. However, selecting the most informative imaging features by machine-learning requires many cases. While large publically-available datasets of people with dementia or prodromal disease exist for Magnetic Resonance Imaging (MRI), comparable datasets are missing for Magnetoencephalography (MEG). MEG offers advantages in its millisecond resolution, revealing physiological changes in brain oscillations or connectivity, before structural changes are evident with MRI. We introduce a MEG dataset with 324 individuals: patients with MCI and healthy controls. Their brain activity was recorded while resting with eyes closed, using a 306-channel MEG scanner at one of two sites (Madrid or Cambridge), enabling tests of generalization across sites. A T1-weighted MRI is provided to assist source localisation. The MEG and MRI data can be formatted according to international BIDS standards, and analysed freely on the DPUK platform (https://portal.dementiasplatform.uk/Apply).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by: EU JNPD (MR/P502017/1), MRC (SUAG/010-RG91365); the Wellcome Trust (103838) and National Institute for Health Research Cambridge Biomedical Research Centre; two consecutive projects by the Spanish Ministry of Economy and Competitiveness, PSI2009-14415-C03-01 and PSI2012-38375-C03-01.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local Ethics Committees at Cambridge University and Centre for Biomedical Technology (CTB), Madrid.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are accessible on the UK's Dementia Platform (DPUK): https://portal.dementiasplatform.uk/CohortDirectory/Item?fingerPrintID=BioFIND https://doi.org/10.48532/007000